Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
Launched by FLORIDA STATE UNIVERSITY · Feb 25, 2023
Trial Information
Current as of October 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called Computerized Anxiety Sensitivity Treatment (CAST) to see if it can help reduce anxiety and related symptoms in older adults who have mild cognitive impairment (MCI) or mild Alzheimer's disease and related dementias (ADRD). The trial also aims to find out if CAST can lessen the burden experienced by caregivers of these individuals. Participants will take part in six in-person visits, which include assessments and treatment sessions, as well as complete short daily surveys over three weeks to monitor their anxiety levels.
To join the study, you must be at least 60 years old if you are the patient, and have a caregiver who is at least 18 years old. Both the patient and caregiver need to have a supportive relationship. The patient should show some signs of anxiety and have specific scores on mental assessments. Participants will have the opportunity to benefit from a structured program that may improve their quality of life and that of their caregivers. If you or your loved one meet these criteria and are interested, the study is currently recruiting participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • DYAD
- • Patient age 60+
- • Care partner 18+
- • Has care partner who will participate ("someone you have a reciprocal relationship with who provides you with emotional or physical support and helps with decision-making. This could be a spouse or significant other, relative, or close friend whom you spend a significant amount of time with.")
- • Has smartphone or access to Wi-Fi
- • EITHER
- • Score of 20 or above on the PROMIS-Anxiety short form (patient only) OR
- • Score of 5 or above on SSASI (patient only) OR
- • Score of 31 or above on NIH Toolbox Perceived Stress Scale score (patient only)
- • AND EITHER
- • 1. Participant MoCA score is between 17 to 26
- • OR
- • 2. Participant Memory Complaint Scale score 3 or greater
- • OR
- • 3. Care partner quick dementia rating scale score between 2 to 12.5
- Exclusion Criteria:
- • PATIENT
- • Issues with seeing or hearing that would prevent reading or listening to computer presentations
- • Medical conditions that would preclude participation in study
- • Severe mental illness (e.g., schizophrenia, unmedicated bipolar disorder)
- • CARE PARTNER
- • Issues with seeing or hearing that would prevent reading or listening to computer presentations
- • Medical conditions that would preclude participation in study
- • Severe mental illness (e.g., schizophrenia, unmedicated bipolar disorder)
About Florida State University
Florida State University (FSU) is a prestigious public research institution located in Tallahassee, Florida, known for its commitment to advancing knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, FSU leverages its extensive academic resources and expertise to conduct rigorous research aimed at improving patient outcomes and contributing to the medical community. The university fosters a collaborative environment that brings together multidisciplinary teams to design, implement, and analyze clinical studies, ensuring adherence to the highest ethical and scientific standards. Through its clinical trials, FSU aims to address critical health challenges and translate research findings into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Athens, Ohio, United States
Columbus, Ohio, United States
Tallahassee, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials